South Korea · Delayed Price · Currency is KRW BioSmart Statistics
Total Valuation
BioSmart has a market cap or net worth of KRW 78.98 billion. The enterprise value is 177.12 billion.
| Market Cap | 78.98B |
| Enterprise Value | 177.12B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
BioSmart has 25.27 million shares outstanding. The number of shares has increased by 12.98% in one year.
| Current Share Class | 25.27M |
| Shares Outstanding | 25.27M |
| Shares Change (YoY) | +12.98% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 24.54% |
| Owned by Institutions (%) | 5.68% |
| Float | 18.81M |
Valuation Ratios
The trailing PE ratio is 6.91.
| PE Ratio | 6.91 |
| Forward PE | n/a |
| PS Ratio | 0.15 |
| PB Ratio | 0.41 |
| P/TBV Ratio | 0.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 5.36 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.37, with an EV/FCF ratio of -7.94.
| EV / Earnings | 15.47 |
| EV / Sales | 0.34 |
| EV / EBITDA | 5.37 |
| EV / EBIT | 6.85 |
| EV / FCF | -7.94 |
Financial Position
The company has a current ratio of 1.75, with a Debt / Equity ratio of 0.40.
| Current Ratio | 1.75 |
| Quick Ratio | 0.28 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | 2.27 |
| Debt / FCF | -3.48 |
| Interest Coverage | 9.54 |
Financial Efficiency
Return on equity (ROE) is 7.49% and return on invested capital (ROIC) is 8.11%.
| Return on Equity (ROE) | 7.49% |
| Return on Assets (ROA) | 5.78% |
| Return on Invested Capital (ROIC) | 8.11% |
| Return on Capital Employed (ROCE) | 11.94% |
| Weighted Average Cost of Capital (WACC) | 5.25% |
| Revenue Per Employee | 3.05B |
| Profits Per Employee | 67.74M |
| Employee Count | 169 |
| Asset Turnover | 1.76 |
| Inventory Turnover | 7.49 |
Taxes
In the past 12 months, BioSmart has paid 5.56 billion in taxes.
| Income Tax | 5.56B |
| Effective Tax Rate | 29.43% |
Stock Price Statistics
The stock price has decreased by -6.99% in the last 52 weeks. The beta is 0.66, so BioSmart's price volatility has been lower than the market average.
| Beta (5Y) | 0.66 |
| 52-Week Price Change | -6.99% |
| 50-Day Moving Average | 4,080.30 |
| 200-Day Moving Average | 3,688.30 |
| Relative Strength Index (RSI) | 29.09 |
| Average Volume (20 Days) | 482,355 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioSmart had revenue of KRW 515.82 billion and earned 11.45 billion in profits. Earnings per share was 452.52.
| Revenue | 515.82B |
| Gross Profit | 87.96B |
| Operating Income | 27.07B |
| Pretax Income | 18.89B |
| Net Income | 11.45B |
| EBITDA | 34.19B |
| EBIT | 27.07B |
| Earnings Per Share (EPS) | 452.52 |
Balance Sheet
The company has 25.72 billion in cash and 77.67 billion in debt, with a net cash position of -51.95 billion or -2,055.34 per share.
| Cash & Cash Equivalents | 25.72B |
| Total Debt | 77.67B |
| Net Cash | -51.95B |
| Net Cash Per Share | -2,055.34 |
| Equity (Book Value) | 194.90B |
| Book Value Per Share | 5,873.64 |
| Working Capital | 68.80B |
Cash Flow
In the last 12 months, operating cash flow was 14.73 billion and capital expenditures -37.04 billion, giving a free cash flow of -22.31 billion.
| Operating Cash Flow | 14.73B |
| Capital Expenditures | -37.04B |
| Depreciation & Amortization | 7.12B |
| Net Borrowing | 19.14B |
| Free Cash Flow | -22.31B |
| FCF Per Share | -882.71 |
Margins
Gross margin is 17.05%, with operating and profit margins of 5.25% and 2.22%.
| Gross Margin | 17.05% |
| Operating Margin | 5.25% |
| Pretax Margin | 3.66% |
| Profit Margin | 2.22% |
| EBITDA Margin | 6.63% |
| EBIT Margin | 5.25% |
| FCF Margin | n/a |
Dividends & Yields
BioSmart does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.98% |
| Shareholder Yield | -12.98% |
| Earnings Yield | 14.49% |
| FCF Yield | -28.25% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 20, 2010. It was a reverse split with a ratio of 0.16667.
| Last Split Date | Sep 20, 2010 |
| Split Type | Reverse |
| Split Ratio | 0.16667 |
Scores
BioSmart has an Altman Z-Score of 2.86 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.86 |
| Piotroski F-Score | 4 |